Novo detemir “approvable”
Executive Summary
Novo Nordisk receives "approvable" letter for its long-acting insulin analog insulin detemir Oct. 7...
You may also be interested in...
Novo detemir approval timeline
Novo-Nordisk expects mid-2005 approval for long-acting insulin analog detemir following submission of additional data to FDA, CEO Lars Rebien Sorensen says. FDA requested more clinical information in Oct. 7 "approvable letter" (1"The Pink Sheet" Oct. 13, 2003, In Brief). Novo believes the request can be met through a "short-term" PK/PD study to assess ethnic differences between patients and data from an ongoing trial...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.